MH
Therapeutic Areas
Catalyst Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AGAMREE® (vamorolone) | Duchenne Muscular Dystrophy (DMD) | Approved/Commercial |
| FIRDAPSE® (amifampridine) | Lambert-Eaton Myasthenic Syndrome (LEMS) | Approved/Commercial |
Leadership Team at Catalyst Pharmaceuticals
RD
Rich Daly
President and Chief Executive Officer
WA
Will Andrews, MD
Chief Medical Officer
AB
Angie Bechan
Executive Vice President, Chief Corporate Affairs Officer
TB
Tara Bey
Vice President, Quality
JD
Jeff Del Carmen
Executive Vice President and Chief Commercial Officer
BE
Brian Elsbernd
Chief Legal and Compliance Officer
PF
Paul Friel
Executive Vice President, Corporate Operations
MK
Mike Kalb
Executive Vice President and Chief Financial Officer
SM
Steve Miller, PhD
Executive Vice President, Chief Operations Officer, and Chief Scientific Officer
GR
Gregg Russo
Chief Human Resources Officer